Recap: Amneal Pharmaceuticals Q1 Earnings - Amneal Pharmaceuticals (NASDAQ:AMRX)

Amneal Pharmaceuticals AMRX reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM.

Here's what investors need to know about the announcement.

Amneal Pharmaceuticals missed estimated earnings by 7.69%, reporting an EPS of $0.12 versus an estimate of $0.13.

Revenue was up $4.53 million from the same period last year.

Last quarter the company missed on EPS by $0.02 which was followed by a 2.99% increase in the share price the next day.

Here's a look at Amneal Pharmaceuticals's past performance:

Quarter	Q4 2021	Q3 2021	Q2 2021	Q1 2021
EPS Estimate	0.20	0.20	0.19	0.18
EPS Actual	0.18	0.21	0.25	0.20
Revenue Estimate	537.35M	545.06M	523.25M	515.34M
Revenue Actual	536.90M	528.59M	535.08M	493.11M

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Amneal Pharmaceuticals management provided guidance for FY 2022, expecting earnings between $0.8 and $0.85 per share.

To track all earnings releases for Amneal Pharmaceuticals visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.